Evidence map›Paper›PMID 42363698›Full record

ReviewCardiovascular therapeutics2026

Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy.

Yusof Kamisah, Hamat Hamdi Che Hassan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yusof KamisahDepartment of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ukm.my.ORCID https://orcid.org/0000-0002-9363-8235
Hamat Hamdi Che HassanCardiovascular and Respiratory Research Group, Universiti Kebangsaan Malaysia, Bandar Baru Bangi, Selangor, Malaysia, ukm.my.ORCID https://orcid.org/0000-0003-0778-0815

Funding

Universiti Kebangsaan Malaysia FF-2024-241
6 · The paper itself

Abstract

Managing acute coronary syndrome (ACS) and atherosclerotic cardiovascular disease remains clinically challenging, requiring a careful balance between ischemic protection and bleeding risk. Antiplatelet therapy is central to the management, with aspirin serving as the cornerstone; however, selection of the second antiplatelet agent in dual antiplatelet therapy (DAPT) remains complex. Clopidogrel, a purinergic receptor subtype Y, G protein-coupled, 12 (P2Y

Indexed as

Acute Coronary SyndromePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsCytochrome P-450 CYP2C19Dual Anti-Platelet TherapyHemorrhageHumansPatient SelectionPharmacogenomic VariantsRisk AssessmentRisk FactorsTreatment OutcomeCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor Antagonists

Identifiers

PMID42363698
PMCPMC13309804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.